FDA Approves Lilly’s Blood Cancer Drug Jaypirca in First-Line CLL, SLL

ACS Issues Recommendations for Design, Reporting of MCED Trials

Cullinan Files NDA Seeking Approval for Zipalertinib as First-Line Treatment With Chemo in NSCLC

UK Researchers to Implement Blood-Based Dementia Markers as Part of £80M Project

Safer, Reprogrammable CAR T-Cell Therapies Heading to Clinical Trials

CellCarta, Imagene AI Partner on Biomarker, CDx Development

Beam Sues YolTech, SeraphaBio Over Alleged Trade Secrets Theft

Foghorn Ends SMARCA2 Collab With Lilly, Cuts Staff By 40 Percent

In Brief This Week: Biomodal, Watchmaker Genomics, Oxford Nanopore, BioMarin, 10x Genomics, Rznomics, More

New Products: Abbott, Roche, Flatiron Health, Caris Life Sciences, EpiSign

People in the News at Memorial Sloan Kettering, Cyted Health, DiaSorin

HUPO Annual Meeting Highlights Advances in Proteomic Technologies, Applications

In Global First, California Now Requires Screening on Routine Synthetic DNA Orders

Renew Bio, Mayo Clinic to Evaluate Nanopore-based cfDNA Assay for Neuroimmunologic Diseases

Metagenomics Firm Biotia Raises $9M in Private Funding

New Method Shows Potential for Advancing Personalized Immunotherapy Without Invasive Tumor Biopsies

UK NICE Backs Arrowhead, Ionis RNA Drugs for Familial Chylomicronaemia Syndrome

Rakovina Using Celvion AI Platform to Advance ATR Inhibitor Program

FIT More Cost-Effective Than Blood-Based MDx, Colonoscopies for CRC Screening, Study Finds

UniQure’s Stock Falters on Latest Huntington’s Disease Trial Data

Amplifyer Bio Developing ‘Priming Agents’ to Boost ctDNA Yields in Liquid Biopsy

Pierre Fabre, Atara Bio Try Again for US Ebvallo Approval

Truvian Health, Siemens Healthineers Ink Development Partnership

Standard BioTools Inks New Agreement to Sell Mass Cytometry Business for $5.5M

GenomeWeb Top 40 Jumps 11 Percent in September, Outpacing Broader Market for Third Straight Month

Vellum Biotech Commercializing Nucleic Acid Extraction Method From Roche

Tiny Health Raises $33M in Series B to Advance Microbiome Analysis Platform

GSK Taps Wave Life Sciences’ siRNA Program, Triggering $12M Milestone Payment

Typewriter Therapeutics Emerges From Stealth With $56M to Develop Gene Insertion Platform

Lantheus Advances GRPR Prostate Imaging Agent After Lutathera Generic Approval

‘Data Leakage’ May Inflate Proteomic Biomarker Panel Performance, Lund Researchers Say

Broad Institute Center Nabs $53M From Novo Nordisk Foundation to Study Diabetes, Obesity

Link Cell Starts Lead CAR T Program, Raises $30M More in Extended Series A

International Team Wins $19.4M NIH Grant to Develop C2N Alzheimer’s Assay as FDA-Approved Test

BillionToOne Adds to Data Supporting Unity Fetal Risk Test With New Prospective Study

Siemens Healthineers, Novo Nordisk Aim to Boost Noninvasive Liver Test Adoption

Senticell Receives $400K NCI Grant to Advanced Lung Cancer Liquid Biopsy

AstraZeneca, Hutchmed Eye US Market for EGFR-MET Lung Cancer Combo

10x Genomics to Launch Sentira for Spatial Data Analysis

Aptadir Therapeutics Raises €40M to Develop RNA Inhibitor Drugs

Haga Bioscience, Imagenomix Partner for AI Spatial Biomarker Analysis in Cancer Pathology

AstraZeneca Invests $2B in Summit Therapeutics, Inks Clinical Trial Collab

VB Spine Nabs FDA Breakthrough Device Designation for Scoliosis Risk Test

Cepheid 13-Target Respiratory Panel Gets FDA Clearance

Astrin Biosciences, OpenLoop Health Ink Distribution Deal for Breast Cancer Rule-Out Test

Along with a POC device, the company has three tests to run on it focused on acute infections, sepsis monitoring, and the prediction of acute kidney injury.

The Cambridge, UK-based company earlier this month obtained a CE-IVD mark for its LVOne test.

As agentic AI transforms scientific work, some worry that it is evolving faster than we can answer important questions about its place in society.

The company provides genotyping, long-read whole genome sequencing, proteomics, and DNA methylation analyses for the VA-sponsored program.

The Swiss drugmaker also revealed at its annual Pharma Day that it has halted a CDK4 program.